Replies to post #28263 on The Rising Influence of Rising Affluence

[10nisman]

Wait until, at least American business people, start wearing them to make sure they're at the top of their game before making an important presentation or business decision.

You've got to be joking or you've never worked in corporate America. No highly qualified business person is going to be looking at some glucose monitoring device before making decisions, or giving a presentation.

We're at an interesting crossroad where your doctor, a reasonable diet, an Apple Watch and a Libre 3 can help the average person lead a more healthy life or we can give in to classic American pills-as-a-solution. It's going to be an interesting decade as technology offers the willing excellent solutions to a longer, more healthy life.

The average person has known this and has had access to the key drivers of being healthy their entire lives --- exercise, reasonable diet, doctors, medication, etc. What you're failing to realize is the average person isn't wired to be healthy, but to enjoy delicious unhealthy fatty/sugary foods, regularly enjoying alcoholic drinks, skipping workouts, lounging and binge watching television, etc. Nor does the average person have the economic means to be healthy especially when throwing in busy schedules. Also, the human body naturally decays overtime, and no glucose monitor / Apple watch is going to stop that. So, unless you're planning on rewiring the average human, or making healthy foods reasonably priced and taste like chocolate cake or ice cream, no technology is going to change the desire of the average person to enjoy life to the fullest by consuming large portions of very unhealthy food and drinks, and engaging in risky behaviors.

[DewDiligence]

Ozempic and other GLP-1 agonists have manifold safety and tolerability issues including a boxed warning for thyroid cancer. They also cause loss of muscle mass, which is especially worrisome for the elderly.

The triple-agonist (GLP-1, GIP, Glucagon) from LLY that generated oohs and aahs when LLY reported the phase-2 data a few days ago has even worse safety and tolerability issues, including cardiac arrhythmias—see #msg-172233230.